Current treatment landscape for kidney cancer

Robert Jones, MD, PhD, University of Glasgow & Beatson West of Scotland Cancer Centre, Glasgow, UK, gives an outline of the treatment landscape for kidney cancer, discussing the wide range of first-line treatment options, and highlighting challenges associated with treatment selection. In particular, Prof. Jones discusses the results of the Phase III CLEAR trial (NCT02811861) investigating lenvatinib plus everolimus or lenvatinib plus pembrolizumab versus sunitinib alone for the treatment of advanced renal cell carcinoma. He also outlines quality-of-life data from the CheckMate 9ER study (NCT03141177) investigating nivolumab combined with cabozantinib versus sunitinib alone. For the treatment of non-clear cell renal carcinoma, Prof. Jones summarizes the results of a Phase II randomized trial (NCT02761057) investigating sunitinib, cabozantinib, crizotinib and savolitinib as monotherapies. This interview took place during the 2021 Genitourinary Cancers Symposium.